1European Society of Hypertension. European society of eardiology guidelines for the management of arterial hypertension[J].J Hypertens,2003,21:1011.
21999 World Health Organization. International society of hypertension guiderlines for the management of hypertension. Guidelines subcommittee[J].J Hypertens. 1999,17:151.
3Chobanian AV, Bakris GL,Black Hra,et al.The seventh report of the joint national committee on prevention,detection,evaluation,and treatment of high blood pressure[J].JAMA,2003,289:2560-2571.
61999 World Health Organization. International society of hypertension guidelines for the management of hypertension. Guidelines subcommittee [J]. J Hypertens, 1999,17:151.
7ALLHAT officers and coordinators for the ALLHAT Collaborative Re search Group.Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthaldone[J].JAMA,2000,283:1967.
8Marre M,Grarcia Puij J,Kokot F.The extend of microalbuminuria re duction with indapamide SR in elderly hypertensive type 2 diabetic patients:the NESTOR study [J]. J Hypertens,2003,21 (supp 14):S 183.
9Staessen JA,Fagard R,Thijs L,et al.The systolic hypertension in Europe (Syst-Eur)trial investigators,Randomised double- blind comparison placebo and active treatment for older patients with isolated systolic hypertension[J].Lancet, 1997,350:757.
二级参考文献51
1Burnier M, Brunner H R. Angiotensin receptor antagonists[J].Lancet,2000, 355: 637-645.
2Matsoukas J M, Bigam G, Zhou N, et al.^1H-NMR studies of [Sar^1] angiotensin Ⅰ conformation by nuclear Over- hause effect spectroscopy in the rotating frame (ROESY): Clustering of the aromatic rings in dimethylsulfoxide[J].Peptides,1990,11:359-366.
3Fermandjian S, Morgat J L, Fromageot P. Studies of angiotensin Ⅱ conformation by circular dichroism[J].Eur J Biochem, 1971, 24: 252-258.
4Hsieh K, Marshall O R. Role of the C-terminal carboxyLate in angiotensin Ⅱ activity: alcohol, ketone, and ester analogues of angiotensin Ⅱ[J]. J Med Chem, 1986, 29: 1968-1971.
5Matsoukas J M, Polevaya L, Ancans J, et al. The design and synthesis of a potent angiotensin Ⅱ cyclic analogue confirms the ring cluster receptor conformation of the hormone angiotensin Ⅱ [J]. Bioorg Med Chem, 2000, 8:1-10.
6Ries U J, Mihm G, Narr B, et al. 6-Substituted benzimidazoles as new nonpeptide angiotensin Ⅱ receptor antagonists : synthesis, biological activity, and structure-activity relationships[J]. J Med Chem,1993, 36(25) : 4040-4051.
7Keenan R M, Weinstock J, Pinkelstein J A, et ai. Potent nonpeptide angiotensin Ⅱ receptor antagonists. 2. I-(Carboxybenzyl)imidazole- 5- acrylic acids[J]. J Med Chem,1993, 36(13):1880-1892.
8Wexler R R, Greenlee W J, Irvin J D, et al. Nonpeptide angiotensin Ⅱ receptor antagonists: the next generation in antihypertensive therapy[J]. J Med Chem, 1996, 39(3) :625-656.
9Mealy N, Castanet J. F.Aisartan Potassium[J]. Drugs Fut,1996, 21: 139-142.
10Kohara Y, Kubo K, Imamiya E, et al. Synthesis and angiotensin Ⅱ receptor antagonistic activities of benzirnidazole derivatives bearing acidic heterocycies as novel tetrazole bioisosteres[J]. J Med Chem, 1996. 39(26), 5228-5235.
